Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 9, 2019
Reporting Period: Event-based (September 9-10, 2019)
Business Context: The Company is an emerging growth company incorporated in Nevada. This filing serves as a Regulation FD disclosure regarding an upcoming investor presentation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a corporate event and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely announces a scheduled presentation at the H.C. Wainwright 21st Annual Global Investment Conference in New York.
Guidance, Outlook, and Risks
- Management Commentary: The Company will present information to investors on September 9 and 10, 2019.
- Exhibit Status: The presentation materials (Exhibit 99.1) are furnished but not deemed "filed" under Section 18 of the Exchange Act and are not incorporated by reference into other filings.
- Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Verify the content of the presentation furnished as Exhibit 99.1 for any forward-looking statements or strategic updates.
- Confirm the Company's status as an emerging growth company and any associated election regarding extended transition periods for accounting standards.
- Review subsequent filings (e.g., 10-Q or 10-K) for actual financial performance data, as this 8-K contains no financial figures.